Home › Forums › Main Forum › Experts Corner › HCV Treatment Options 2017/2018: What’s Here and What’s Coming

Viewing 3 posts - 1 through 3 (of 3 total)
  • Author
    Posts
  • 13 August 2017 at 6:20 am #26737
    dope-on-a-rope.jpgDr James
    • Guardian Angel
    • ★★★★★
    @fixhepc

    Here is a slide presentation from Clinical Care Options called HCV Treatment Options in 2017/2018:
    What’s Here and What’s Coming Soon

    CCO_Hepatitis_Annual_Update_2017_Plenary_Downloadable_1-2.pdf

    CCO_Hepatitis_Annual_Update_2017_Plenary_Downloadable_1-2.ppt

    YMMV

    13 August 2017 at 4:08 pm #26742
    Avatar photoklhilde
    • Guardian Angel
    • ★★★★★
    @klhilde

    Okay, some questions …

    First:
    For Genotypes 2,4,5,6 they are not recomending Sof/Dac. Is this due to inferiority or has BMS simply not persued approval? Are the recomendations the same in Europe?

    For people in these genotypes who need generics, is there any reason to not choose the Sof/Dac combo?

    Second:
    Where are we standing now (or soon) on the availabilities of generic forms of the newer combos. (Sof/Vel/Vox, and AbbVie’s combos, etc.)

    14 August 2017 at 5:54 am #26744
    dope-on-a-rope.jpgDr James
    • Guardian Angel
    • ★★★★★
    @fixhepc

    Hi Kevin,

    Yes this is a USA based slant, so Sof/Dac does not feature. It does with EASL – you can see their easy to read tables here: https://fixhepc.com/genotype-specific-hepc-treaments.html

    Sof/Dac has been used in about 1 million Egyptian GT4 patients so there is no doubt it works well. We still have 100% SVR for it in GT2 and last time I looked that was 44/44 so it’s pretty solid there. With GT5 and GT6 we also have 100% but the numbers are pretty small – about a dozen patients all up.

    At the moment there is no generic Vosevi coming soon that I’m aware of. There have never been generics of AbbVie stuff however that may well change over the course of the next year.

    YMMV

  • Author
    Posts
Viewing 3 posts - 1 through 3 (of 3 total)
  • You must be logged in to reply to this topic.